While a number of therapies that target cytokines that act downstream of the epithelium, such as IL-5 and IL-4/IL-13, have demonstrated efficacy in asthma [50], targeting epithelial alarmins, which are broad upstream mediators of the inflammatory response, has become an attractive therapeutic option in asthma management [51]. The gene discussed is IL13; the disease is asthma.